HIGHLIGHTS
SUMMARY
The authors aimed to quantitatively evaluate the benefits and risks of the COVID-19 vaccine using the MCDA and to rank the COVID-19 vaccine using evidence before and after approval. The authors quantitatively evaluated the benefits and risks of four COVID-19 vaccines (mRNA1273, BNT162b2, Ad26.COV.2, and ChAdOx1-S) using MCDA and ranked the COVID-19 vaccines using evidence before and after approval. The authors assessed two mRNA-based vaccines and two viral_vector-based vaccines that were approved worldwide during the early pandemic: the mRNA-based vaccines BNT162b2 (Pfizer-BioNTech) and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.